Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.